Hereditary haemorrhagic telangiectasia with extensive liver involvement is not caused by either HHT1 or HHT2

M Piantanida, E Buscarini, C Dellavecchia, A Minelli, A Rossi, L Buscarini, C Danesino

Abstract

Hereditary haemorrhagic telangiectasia (HHT) is a genetically heterogeneous dominant disorder. Two disease loci have been mapped to chromosomes 9q3 and 12q. In a large pedigree, with an unusually high number of patients with liver vascular malformations, both previously mapped loci have been excluded. The loci for two other inherited vascular malformation diseases, cerebral cavernous malformations and multiple cutaneous and mucosal venous malformations, have also been excluded. Thus we conclude that at least a third, as yet unmapped, HHT locus does exist, possibly associated with high frequency of liver involvement.

Key words: HHT; Rendu-Osler-Weber; genetic heterogeneity; liver involvement.

Hereditary haemorrhagic telangiectasia, also known as Rendu-Osler-Weber disease, is a well known, although rare, autosomal dominant disorder. Telangiectases formed by dilated capillary vessels on skin and mucosa usually cause nasal and gastrointestinal bleeding. Other angiodysplastic lesions include arteriovenous malformations and angiomata. Although commonest in the pulmonary circulation, arteriovenous shunts can potentially affect every organ, and cause gastrointestinal haemorrhage, hepatic fibrosis, hyperdynamic circulation, and neurological symptoms owing to emboli or cerebral vascular malformations.

A disease locus, HHT1, was assigned by linkage analysis to chromosome 9q34. After further refinement of the positional mapping, a candidate gene approach succeeded in identifying mutations in the gene coding for endoglin, a membrane glycoprotein binding transforming growth factor beta (TGF-β), expressed at high levels in endothelial cells. Genetic heterogeneity of HHT has been reported, possibly reflecting heterogeneity of clinical manifestations.

A second locus, HHT2, was recently assigned to chromosome 12q. One family was reported to be linked to markers of chromosome 3p22, in a region in which the gene for TGF-β receptor type II had been mapped, but...
further studies on the same family resulted in stronger evidence of linkage with chromosome 12 markers. At present no families have been reported for which both HHT1 and HHT2 have been excluded.

Loci for cerebral cavernous malformations (CCM1) and multiple cutaneous and mucosal venous malformations (VMCM) were assigned by linkage analysis to chromosomes 7q11-q21 and 9p13 respectively. Both are autosomal dominant disorders with some features resembling HHT.

Methods

FAMILY DESCRIPTION

We studied a large HHT family with 30 affected subjects (fig 1). In 13 female patients we documented angiodysplastic liver involvement. In two male patients, in addition to telangiectases, we found anomalies of the splenic artery (fig 2, No 544) and nodular steatosis of the liver (fig 1, No 428).

In one patient the hepatic arteriovenous malformations caused symptomatic hyperdynamic circulation which was successfully treated by embolisation of hepatic artery branches.

POLYMORPHISM TYPING AND LINKAGE ANALYSIS

Genomic DNA extraction from samples of citrated venous blood and ABO blood group typing were performed by routine techniques. The short tandem repeat polymorphisms were typed by PCR amplification in an 8 μl reaction volume containing 20 to 100 μg of genomic DNA as template, 330 nmol/l each primer, 200 μmol/l each dCTP, dGTP, and dTTP, 25 μmol/l dATP, 1 μCi [α35S]dATP, 50 mmol/l KCl, 10 mmol/l Tris, 1·5 mmol/l MgCl2, 0·1% Triton X-100, 0·01% gelatine, and 0·2 U Taq polymerase. Samples were over-

Figure 2  Multipoint linkage analysis plots for disease locus HHT versus marker loci. Candidate regions are represented by the solid bars. Loci in italics were not scored in the reported family. (A) ABO and D9S103 (MFD77) exclude locus HHT1; (B) D12S1042 (CHLC.GATA27A06), D12S339 (AFM294wc5), and D12S375 (CHLC.GATA3F02) exclude HHT2; (C) D3S3038 (CHLC.GATA73D01), D3S2432 (CHLC.GATA27C08), and D3S1619 (AFM350tfl) exclude the chromosome 3p22 region; (D) D7S1870 (AFMa0060xc9) and COL1A2 exclude CCM1; (E) D9S925 (CHLC.GATA27A11) and D9S319 (CHLC.GATA12C06) exclude VMCM.
laid with 10 µl of mineral oil, denatured at 96°C for five minutes, and processed for 30 cycles (94°C for 40 seconds, 57°C for 40 seconds, 72°C for 40 seconds), followed by a final extension step at 72°C for five minutes. Reaction volume was mixed with 10 µl formamide, denatured at 96°C for five minutes, and 5 to 7 µl of the mix were loaded on a 6% polyacrylamide sequencing gel. PCR products were detected by exposing dried gels to x ray films. Primer sequences are reported in GDB (Johns Hopkins University, Baltimore, USA). Multipoint linkage analysis was performed by the computer program package FASTLINK,17 assuming equal sex recombination fractions and a frequency of 0:0001 for the allele causing the HHT phenotype. Marker allele frequencies were estimated from the family itself. A reduced age dependent penetrance was used (penetrance 0-16, 0-41, 0-57, 0-74, 0-90, and 0-97 at age class <20, 21–30, 31–40, 41–50, 51–60, and >60 years respectively). Affection status was scored as unknown in at risk subjects with fewer than five cutaneous or mucosal telangiectases or fewer than 10 episodes of epistaxis per year.

The order of loci and the genetic distances between adjacent loci were taken from published18 and online data. Estimated recombination fractions were converted to centimorgans (cM) using the Haldane mapping function.

Results and discussion

Multipoint linkage analysis results are shown in fig 2. Two point linkage analysis with the same markers was not significantly affected using a wide range of penetrance values and allele frequencies, even using a low penetrance model (data not shown).

The HHT1 locus has been mapped in the 2 cM interval between markers D9S560 and D9S61.17 Markers D9S103 and ABO flanking the interval exclude the whole region (fig 2A).

The candidate interval containing the HHT2 locus is flanked by markers D12S339 and D12S345.8 A much larger interval has been excluded in this family (fig 2B).

Markers D3S3038, D3S2432, and D3S1619 exclude a region of about 50 cM including 3p22, and thus exclude the TGF-β receptor type II as a candidate gene (fig 2C). The regions where CCM1 and VMC1 had been mapped were also excluded (fig 2D,E).

Our data indicate the existence of at least a third HHT locus. The high proportion of liver involvement found in our family is quite uncommon in HHT, and was reported in only 8% of HHT patients in a large series.20 We speculate that the high frequency of liver vascular anomalies is the hallmark of a distinct subtype of HHT. Clinical heterogeneity is in agreement with the genetic heterogeneity shown.

We have no explanation for the evident sex bias in liver involvement, but it may just be coincidental since in other families19,22 a male predominance has been reported.

Since no TGF-β binding protein genes other than endoglin and TGF-β receptor type II have been mapped, a systematic linkage mapping search is at the moment the only possible approach and is in progress.

The financial support of Telethon-Italy (grant No E.312) is gratefully acknowledged. We wish to thank Professor G Novelli for his gift of D7S1870 PCR primers and Professor M Fraccaro for helpful discussion.

1 Online Mendelian Inheritance in Man, OMIM. The human genome data base project. Baltimore: Johns Hopkins University, MIM 000306, data last edited November 1995.
10 Online Mendelian Inheritance in Man, OMIM. The human genome data base project. Baltimore: Johns Hopkins University, MIM 000376, data last edited November 1995.
Hereditary haemorrhagic telangiectasia with extensive liver involvement is not caused by either HHT1 or HHT2.

M Piantanida, E Buscarini, C Dellavecchia, A Minelli, A Rossi, L Buscarini and C Danesino

*J Med Genet* 1996 33: 441-443
doi: 10.1136/jmg.33.6.441

Updated information and services can be found at:
http://jmg.bmj.com/content/33/6/441

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/